1. Home
  2. LEGN vs ACIW Comparison

LEGN vs ACIW Comparison

Compare LEGN & ACIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • ACIW
  • Stock Information
  • Founded
  • LEGN 2014
  • ACIW 1975
  • Country
  • LEGN United States
  • ACIW United States
  • Employees
  • LEGN N/A
  • ACIW N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • ACIW EDP Services
  • Sector
  • LEGN Health Care
  • ACIW Technology
  • Exchange
  • LEGN Nasdaq
  • ACIW Nasdaq
  • Market Cap
  • LEGN 5.4B
  • ACIW 5.1B
  • IPO Year
  • LEGN 2020
  • ACIW 1995
  • Fundamental
  • Price
  • LEGN $34.00
  • ACIW $44.59
  • Analyst Decision
  • LEGN Strong Buy
  • ACIW Strong Buy
  • Analyst Count
  • LEGN 12
  • ACIW 5
  • Target Price
  • LEGN $77.09
  • ACIW $60.00
  • AVG Volume (30 Days)
  • LEGN 2.0M
  • ACIW 628.8K
  • Earning Date
  • LEGN 08-08-2025
  • ACIW 07-31-2025
  • Dividend Yield
  • LEGN N/A
  • ACIW N/A
  • EPS Growth
  • LEGN N/A
  • ACIW 87.47
  • EPS
  • LEGN N/A
  • ACIW 2.53
  • Revenue
  • LEGN $728,303,000.00
  • ACIW $1,672,834,000.00
  • Revenue This Year
  • LEGN $65.49
  • ACIW $9.14
  • Revenue Next Year
  • LEGN $53.76
  • ACIW $6.78
  • P/E Ratio
  • LEGN N/A
  • ACIW $17.50
  • Revenue Growth
  • LEGN 112.46
  • ACIW 13.11
  • 52 Week Low
  • LEGN $27.34
  • ACIW $35.99
  • 52 Week High
  • LEGN $60.87
  • ACIW $59.71
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 53.16
  • ACIW 33.45
  • Support Level
  • LEGN $33.84
  • ACIW $44.96
  • Resistance Level
  • LEGN $35.29
  • ACIW $47.93
  • Average True Range (ATR)
  • LEGN 1.96
  • ACIW 0.99
  • MACD
  • LEGN 0.24
  • ACIW -0.06
  • Stochastic Oscillator
  • LEGN 52.16
  • ACIW 9.92

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About ACIW ACI Worldwide Inc.

ACI Worldwide Inc develops, markets and installs a portfolio of software products focused on facilitating electronic payments. The firm also leverages its distribution network in the Americas; Europe, the Middle East, and Africa, or EMEA; and Asia-Pacific regions to sell software developed by third parties. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but majority of the revenue is generated in the United States and EMEA regions.

Share on Social Networks: